Company news

Unicycive Therapeutics, Inc. news in 2022

Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock

December 28, 2022

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

December 27, 2022

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

December 21, 2022

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

November 20, 2022

Unicycive Announces Third Quarter Financial Results and Provides Business Update

November 13, 2022

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis

November 9, 2022

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

September 6, 2022

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022

August 23, 2022

Unicycive Announces Second Quarter Financial Results and Provides Business Update

August 14, 2022

Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets

July 17, 2022

Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

June 1, 2022

Unicycive Announces First Quarter Financial Results and Provides Business Update

May 11, 2022

Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases

April 13, 2022

Unicycive Announces Full Year 2021 Financial Results and Provides Business Update

March 30, 2022

Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022

March 22, 2022

Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting

February 1, 2022

Decks in 2022